Kevin Brittan

Kevin Brittan

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 June 2023 in Viruses
Verified
Journal Article
Open access
PDF file
Busara SongtaninBusara Songtanin
Busara Songtanin
AMAdebayo James James Molehin
Adebayo James James Molehin
KBKevin Brittan
Kevin Brittan
WMWuttiporn Manatsathit
Wuttiporn Manatsathit
Kenneth NugentKenneth Nugent
Kenneth Nugent
According to the World Health Organization, approximately 20 million people worldwide are infected annually with the hepatitis E virus (HEV). There are four main genotypes of HEV. Genotype 1 and genotype 2 are common in developing countries and are transmitted by contaminated water from a fecal–oral route. Genotype 3 and genotype 4 are common in developed countries and can lead to occasional transmission to humans via undercooked meat. Hepatitis E virus 1 and HEV3 can lead to fulminant hepatitis, and HEV3 can lead to chronic hepatitis and cirrhosis in immunocompromised patients. The majority of patients with HEV infection are asymptomatic and usually have spontaneous viral clearance without treatment. However, infection in immunocompromised individuals can lead to chronic HEV infection. Both acute and chronic HEV infections can have extrahepatic manifestations. No specific treatment is required for acute HEV infection, no treatment has been approved in chronic infection, and no HEV vaccine has been approved by the (United States) Food and Drug Administration. This review focuses on the molecular virology (HEV life cycle, genotypes, model systems, zoonosis), pathogenesis, clinical manifestation, and treatment of chronic HEV infection, especially in immunocompromised patients, to provide clinicians a better understanding of the global distribution of these infections and the significant effect they can have on immunocompromised patients.

1 March 2024 in Digestive and Liver Disease
Verified
Journal Article
Closed access
KSKyle Scholten
Kyle Scholten
PTPatrick Twohig
Patrick Twohig
KSKaeli Samson
Kaeli Samson
KBKevin Brittan
Kevin Brittan
AFAlexandra Fiedler
Alexandra Fiedler
MOMarco Olivera
Marco Olivera

6 June 2023 in Preprints.org
Verified
Preprint
Open access
Busara SongtaninBusara Songtanin
Busara Songtanin
AMAdebayo J. Molehin
Adebayo J. Molehin
KBKevin Brittan
Kevin Brittan
WMWuttiporn Manatsathit
Wuttiporn Manatsathit
Kenneth NugentKenneth Nugent
Kenneth Nugent
According to the World Health Organization, approximately 20 million people worldwide are infected annually with the hepatitis E virus (HEV). There are 4 main genotypes of HEV. Genotype 1 and genotype 2 are common in developing countries and are transmitted by contaminated water from a fecal-oral route. Genotype 3 and genotype 4 are common in developed countries and can lead to occasional transmission to humans by undercooked meat. Hepatitis E virus 1 and HEV3 can lead to fulminant hepatitis, and HEV3 can lead to chronic hepatitis and cirrhosis in immunocompromised patients. The majority of patients with HEV infection are asymptomatic and usually have spontaneous viral clearance without treatment. However, infection in immunocompromised individuals can lead to chronic HEV infection. Both acute and chronic HEV infections can have extrahepatic manifestations. No specific treatment is required for acute HEV infection, no treatment has been approved in chronic infection and no HEV vaccine has been approved by the (United States) Food and Drug Administration. This review focuses on the molecular virology (HEV life cycle, genotypes, model systems, zoonosis), pathogenesis, clinical manifestation, and treatment of chronic HEV infection, especially in immunocompromised patients, to provide clinicians a better understanding of the global distribution of these infections and the significant effect they can have on immunocompromised patients.

21 October 2023 in Digestive Diseases and Sciences
Verified
Journal Article
Closed access
PDF file
PTPatrick A. Twohig
Patrick A. Twohig
KSKyle Scholten
Kyle Scholten
MSMakayla Schissel
Makayla Schissel
KBKevin Brittan
Kevin Brittan
JBJason Barbaretta
Jason Barbaretta
TPThoetchai Bee Peeraphatdit
Thoetchai Bee Peeraphatdit

1 October 2024 in ACG Case Reports Journal
Verified
Journal Article
Open access
AFAlexandra Fiedler
Alexandra Fiedler
KBKevin Brittan
Kevin Brittan
WMWuttiporn Manatsathit
Wuttiporn Manatsathit
Syndromes characterized by congenital diarrhea, hearing loss, and intrahepatic cholestasis are uncommon and often misdiagnosed as progressive familial intrahepatic cholestasis (PFIC). Recent genetic studies have widened the array of genes linked with cholestatic disorders. Among these, UNC45A has recently been implicated in microvillous inclusion disease (MVID), although only a few cases exist. This case highlights a 20-year-old woman initially diagnosed clinically with PFIC type 1 during childhood. After ileal bypass at age 4 years, she had a resolution of intractable pruritus and cholestasis. Despite remaining symptom-free for over a decade, she returned in adulthood with recurrent cholestatic pruritus. Odevixibat was initiated for presumed PFIC while awaiting additional testing with symptomatic improvement and laboratory normalization. Whole genome sequencing identified novel compound heterozygous mutations in UNC45A and small bowel biopsies confirmed villous atrophy. Odevixibat, currently approved for cholestatic pruritus in PFIC and Alagille syndrome, demonstrates efficacy in managing cholestatic pruritus in MVID.

28 March 2024 in ACG Case Reports Journal
Verified
Journal Article
Open access
KBKevin Brittan
Kevin Brittan
AFAlexandra Fiedler
Alexandra Fiedler
KSKyle Scholten
Kyle Scholten
Busara SongtaninBusara Songtanin
Busara Songtanin
SMShane Manatsathit
Shane Manatsathit
Idiopathic granulomatous hepatitis is a rare condition characterized by hepatic granulomas with constitutional symptoms such as recurrent fevers, myalgias, and hepatosplenomegaly in the absence of infection or inflammatory disorder. Typical treatment and course of this disease consist of a course of steroids with rapid symptom resolution. However, symptoms may recur when steroids are tapered. In these circumstances, azathioprine, methotrexate, infliximab, and adalimumab have demonstrated good response. In this case, we present a patient who developed antidrug antibodies to infliximab and adalimumab and was the first documented case of this disease to be treated with certolizumab pegol. Our case highlights the novel efficacy of certolizumab pegol for idiopathic granulomatous hepatitis and its role in treating idiopathic granulomatous hepatitis with antidrug antibodies.